Disrupting Dengue with an Emerging Markets Launch Strategy Case Solution

This Case is about EMERGING MARKETS, PRODUCT DEVELOPMENT, RISK MANAGEMENT

PUBLICATION DATE: September 26, 2016

Sanofi Pasteur’s recently authorized dengue vaccine, Dengvaxia, was uncommon because it was released in the Philippines and various other at-risk nations. By opting to “turn the design” – launch in an arising market setting rather than industrialized markets – it needed to conquer numerous challenges throughout the worth chain, from enrollment to funding to provide. The business invested 20 years and also invested $1.7 billion to establish Dengvaxia, taking numerous high-risk choices and making compromises along the way. The scenario feature the stakeholder interdependencies and also unpredictabilities that stayed as the vaccine application program sneaked more detailed. It might possibly use a plan for various other if effectively fixed.

Share This